Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 6: 1234 - 1242

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230630.004

Research Articles

Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula (补肾益气方): a prospective randomized controlled study

  • Longci PAN ,
  • Chunhui QI ,
  • Xubo SHEN ,
  • Yixian HUANG ,
  • Xinrong YANG ,
  • Xianjun SUN
Expand
  • 1 Department of Tradition Chinese Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China
    2 Department of Oncology, Shanghai Qingpu District Hospital of Traditional Chinese Medicine (the Clinical Base of The Institutes of Integrative Medicine, Fudan University), Shanghai 201799, China
    3 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
    4 Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China

Received date: 2022-09-12

  Accepted date: 2022-12-23

  Online published: 2023-06-30

Supported by

Innovative Research Team of High-Level Local University in Shanghai; the Discipline Construction and Talent Training Project in Qingpu District of Shanghai: the Fourth Round of Key Discipline Construction in Qingpu District(WZ2019-04);Fourth Round of Discipline Leader Training Plan in Qingpu District(WD2019-17/39 and WT-2019-02);Project of Qingpu District Science and Technology Committee: Study on the Mechanism of Icariin Regulating GR in the Treatment of OIPN(QKY2020-34)

Fold

Abstract

OBJECTIVES: To analyze the distribution characteristics of Traditional Chinese Medicine (TCM) syndromes in patients with oxaliplatin-induced peripheral neuropathy (OIPN) and observe the clinical efficacy of Bushen Yiqi formula (补肾益气方, BSYQF) in treating patients with OIPN.
METHODS: A total of 89 patients with OIPN were enrolled in this study. The TCM syndrome characteristics were investigated by frequency analysis methodology after collecting and analyzing the TCM syndrome elements of the patients with the OIPN TCM syndrome element scale. Further, 62 cases of cold-dampness obstruction syndrome and kidney-Qi deficiency and cold syndrome were selected and randomly divided into the control group (n = 31) and the treatment group (n = 31). The patients in the treatment group were treated with modified BSYQF, while those in the control group were treated with mecobalamin tablets for 3 weeks. The Levi sensory neurotoxicity score and the neuro-electrophysiological changes were observed before and after the treatment in both groups.
RESULTS: The distribution of TCM syndrome types in 89 patients with OIPN were in order of kidney-Qi deficiency and cold syndrome (44 cases), cold-dampness obstruction syndrome (18 cases), Yin deficiency of liver and kidney syndrome (11 cases), blood stasis obstruction syndrome (7 cases), and dampness-heat obstruction syndrome (5 cases). Improvement in Levi sensory neurotoxicity score: After 3-week treatment, the total effective rate in the treatment group was higher than that in the control group (P < 0.05). The subgroup analysis showed that the total effective rate in the treatment group of patients with kidney-Qi deficiency and cold syndrome was higher than that in the control group before and after treatment (P < 0.05). Improvement in nerve conduction velocity: The sensory nerve conduction velocity of bilateral ulnar nerves improved in the control group after treatment compared with that before treatment (P < 0.05). The sensory and motor nerve conduction velocities of the bilateral ulnar and bilateral peroneal nerves improved in the treatment group compared with those before treatment and after treatment in the control group (P < 0.05).
CONCLUSIONS: The modified BSYQF had a definite therapeutic effect on the OIPN in patients with kidney-Qi deficiency and cold syndrome and those with cold-dampness obstruction syndrome. It could effectively reduce the grade of peripheral nerve toxicity and improve nerve conduction velocity, and its curative effect was better than that of mecobalamin tablets.

Key words： oxaliplatin; peripheral nervous system diseases; syndrome and complex; nerve conduction velocity; Bushen Yiqi formula

Cite this article

Longci PAN , Chunhui QI , Xubo SHEN , Yixian HUANG , Xinrong YANG , Xianjun SUN . Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula (补肾益气方): a prospective randomized controlled study[J]. Journal of Traditional Chinese Medicine, 2023 , 43(6) : 1234 -1242 . DOI: 10.19852/j.cnki.jtcm.20230630.004

References

1. Ter Veer E, van Oijen MGH, van Laarhoven HWM. S-1 with leucovorin and oxaliplatin for advanced gastric cancer. Lancet Oncol 2016; 17: e41.
2. Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017; 9: 907-20.
3. Neuzillet C, Gaujoux S, Williet N, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018; 50: 1257-71.
4. Conteduca V, Gurioli G, Rossi L, et al. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer 2018; 18: 1267.
5. André T, Vernerey D, Mineur L, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage Ⅲ colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) france, phase Ⅲ trial. J Clin Oncol 2018; 36: 1469-77.
6. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase Ⅲ trial N08CB (Alliance). J Clin Oncol 2015; 33: 3416-22.
7. Drott J, Fomichov V, Starkhammar H, B?rjeson S, Kjellgren K, Berter? C. Oxaliplatin-induced neurotoxic side effects and their impact on daily activities: a longitudinal study among patients with colorectal cancer. Cancer Nurs 2019; 42: E40-8.
8. Soveri LM, Lamminm?ki A, H?nninen UA, Karhunen M, Bono P, Osterlund P. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 2019; 58: 398-406.
9. The Ministry of Health of the People's Republic of China. Guiding Principles for Clinical research of new Chinese medicine (Volume 1). Beijing: the Ministry of Health of the People's Republic of China, 1992: 210-5.
10. Zheng XY. Guiding Principles for clinical research of new Chinese medicine. Beijing: the Medicine Science and Technology Press of China, 2002: 115-9.
11. Deng TT, Deng ZY, Luo YK. TCM syndrome specification. Guangzhou: Guangzhou Science and Technology Press, 1990: 55-9, 86-9, 168-70.
12. Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 2012; 67: 1025-39.
13. Schmitt LI, Leo M, Kleinschnitz C, Hagenacker T. Oxaliplatin modulates the characteristics of voltage-gated calcium channels and action potentials in small dorsal root ganglion neurons of rats. Mol Neurobiol 2018; 55: 8842-55.
14. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci USA 2012; 109: 6704-9.
15. Li L, Shao J, Wang J, et al. MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats. Neuropharmacology 2019; 153: 111-20.
16. Riva B, Dionisi M, Potenzieri A, et al. Oxaliplatin induces pH acidification in dorsal root ganglia neurons. Sci Rep 2018; 8: 15084.
17. Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One 2017; 12: e0170814.
18. Livni L, Lees JG, Barkl-Luke ME, Goldstein D, Moalem-Taylor G. Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. Neurosci Lett 2019; 694: 14-9.
19. Hershman DL, Lacchetti C, Dworkin RH, et al. American Society of Clinical O Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-67.
20. Sun XJ, Lü YB, Wang JJ, et al. Differential protein expression profiling by iTRAQ‐2D‐LC‐MS/MS of rats treated with oxaliplatin. J Cell Biochem 2019;120: 18128-41.
21. Kong LW, Wu JF, Lin Y, et al. Bushen Yiqi granule inhibits atopic dermatitis via improving central and skin hypothalamic-pituitary-adrenal axis function. PloS One 2015; 10: e0116427.
22. Cui J, Xu F, Tang Z, et al. Bu-Shen-Yi-Qi formula ameliorates airway remodeling in murine chronic asthma by modulating airway inflammation and oxidative stress in the lung. Biomed Pharmacother 2019; 112: 108694.
23. Wei Y, Luo QL, Sun J, Chen MX, Liu F, Dong JC. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. J Ethnopharmacol 2015; 164: 368-77.
24. Sun XJ, Deng XH, Cai WJ, et al. Icariin inhibits LPS-induced cell inflammatory response by promoting GRα nuclear translocation and upregulating GRα expression. Life Sciences 2018; 195: 33-43.
25. Sun XJ, Cheng HQ, Liu BJ, et al. Icariin reduces LPS induced acute lung injury in mice undergoing bilateral adrenalectomy by regulating GRα. Eur J Pharmacol 2020; 876: 173032.
26. Tian DH. Huang Di Nei Jing Su Wen. Beijing: People's Medical Publishing House, 2005: 181.
27. Wang J. Principles of medicine. Beijing: China Press of Traditional Chinese Medicine, 2009: 235.
Options
Outlines

/

〈 〉